Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Swedish Orphan Biovitrum AB (publ)
XMUN:B6E
|
SE |
|
M
|
McCormick & Company Inc
F:MCX
|
US |
|
T
|
Takeda Pharmaceutical Co Ltd
DUS:TKD
|
JP |
|
S
|
Sixt SE
XMUN:SIX2
|
DE |
|
Tokyo Metro Co Ltd
F:XO7
|
JP |
|
C
|
China Overseas Land & Investment Ltd
SWB:CPP
|
HK |
|
Bilibili Inc
F:71BB
|
CN |
|
M
|
McCormick & Company Inc
XMUN:MCX
|
US |
|
C
|
Canfor Pulp Products Inc
F:8CP
|
CA |
|
China Securities Co Ltd
F:CS0
|
CN |
|
W
|
Woodside Petroleum Ltd
F:WOPA
|
AU |
|
Hello Group Inc
F:1MO
|
CN |
|
V
|
Vicor Corp
F:VCV
|
US |
|
D
|
Deutsche EuroShop AG
XHAM:DEQ
|
DE |
|
F
|
Fraport AG Frankfurt Airport Services Worldwide
XHAM:FRA
|
DE |
|
T
|
Twin Disc Inc
F:TWN
|
US |
|
Pc Partner Group Ltd
SGX:PCT
|
HK |
|
T
|
Toll Brothers Inc
F:TLK
|
US |
|
Cibus Nordic Real Estate AB (publ)
F:6N5
|
SE |
|
M
|
M/I Homes Inc
F:4MI
|
US |
|
T
|
Takeda Pharmaceutical Co Ltd
XMUN:TKD
|
JP |
Wall St Price Targets
B6E Price Targets Summary
Swedish Orphan Biovitrum AB (publ)
According to Wall Street analysts, the average 1-year price target for B6E is 43.84 EUR with a low forecast of 29.24 EUR and a high forecast of 52.31 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is B6E's stock price target?
Price Target
43.84
EUR
According to Wall Street analysts, the average 1-year price target for B6E is 43.84 EUR with a low forecast of 29.24 EUR and a high forecast of 52.31 EUR.
What is the Revenue forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Revenue has been 23%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Net Income forecast for Swedish Orphan Biovitrum AB (publ)?
Projected CAGR
50%
The compound annual growth rate for Net Income over the next 8 years is 50%.
